Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - Priority Announcement: Cardiovascular health across the lifespan

Université Laval

$100,000.00

Imaging Substudy of Bicuspid aortic valve replacement: EvaLuatIon of transcathetEr VERsus Surgery (BELIEVERS) Trial

EF 2024-25

Résumé
Bicuspid aortic valve (BAV) is the most frequent congenital heart condition characterized by the presence of two, rather than three, cusps in the aortic valve. BAV can lead to various complications, including aortic stenosis (narrowing of the valve opening) and aortic regurgitation (leaking of the valve), requiring aortic valve intervention (surgical replacement or repair of the valve and/or of the aorta). This intervention is generally performed using open heart surgery (surgical aortic valve replacement; SAVR). However, transcatheter aortic valve replacement (TAVR) has emerged and provides a much less invasive alternative. However, despite TAVR procedure being approved for the replacement of both tricuspid (normal) aortic valves (TAV) and BAVs, the clinical trials conducted so far have generally excluded patients with BAV. The BELIEVERS randomized trial will thus compare TAVR vs. SAVR in BAV patients with regards to mortality, stroke, rehospitalization and valve reintervention at 3 years. In this CIHR grant application, we propose to take the unique opportunity of the BELIEVERS trial to conduct an echocardiography substudy in order to compare TAVR vs. SAVR with regards to the risk of valve dysfunction (residual valve stenosis, regurgitation, thrombosis) and durability. The echocardiograms performed by the participating sites before the procedure and at 30 days, and annually until 10 years post procedure and will be analyzed in a centralized and standardized manner in the echocardiography core laboratory based at the Québec Heart & Lung Institute. The BELIEVERS trial and the imaging substudy that we propose are the first to determine whether there is a difference between the 2 main types of aortic valve replacement, in terms of prosthetic valve function, durability, and clinical outcomes. If this study demonstrates that TAVR is at least as good as SAVR, this will validate TAVR as a valuable option for the treatment of people with BAV.
Programme
Project Grant - Priority Announcement: Cardiovascular health across the lifespan
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
514442
Name
Pibarot Philippe J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Randomized Controlled Trials
Projecttitle
Imaging Substudy of Bicuspid aortic valve replacement: EvaLuatIon of transcathetEr VERsus Surgery (BELIEVERS) Trial
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Cardiovascular health across the lifespan
Keyworddelim
Aortic Valve Stenosis; Aortopathy; Bicuspid Aortic Valve; Bicuspid Aortic Valve Anatomy; Echocardiography; Imaging Core Laboratory; Interventional Cardiology; Outcomes; Surgical Aortic Valve Replacement; Transcatheter Aortic Valve Replacement
Abstract
Bicuspid aortic valve (BAV) is the most frequent congenital heart condition characterized by the presence of two, rather than three, cusps in the aortic valve. BAV can lead to various complications, including aortic stenosis (narrowing of the valve opening) and aortic regurgitation (leaking of the valve), requiring aortic valve intervention (surgical replacement or repair of the valve and/or of the aorta). This intervention is generally performed using open heart surgery (surgical aortic valve replacement; SAVR). However, transcatheter aortic valve replacement (TAVR) has emerged and provides a much less invasive alternative. However, despite TAVR procedure being approved for the replacement of both tricuspid (normal) aortic valves (TAV) and BAVs, the clinical trials conducted so far have generally excluded patients with BAV. The BELIEVERS randomized trial will thus compare TAVR vs. SAVR in BAV patients with regards to mortality, stroke, rehospitalization and valve reintervention at 3 years. In this CIHR grant application, we propose to take the unique opportunity of the BELIEVERS trial to conduct an echocardiography substudy in order to compare TAVR vs. SAVR with regards to the risk of valve dysfunction (residual valve stenosis, regurgitation, thrombosis) and durability. The echocardiograms performed by the participating sites before the procedure and at 30 days, and annually until 10 years post procedure and will be analyzed in a centralized and standardized manner in the echocardiography core laboratory based at the Québec Heart & Lung Institute. The BELIEVERS trial and the imaging substudy that we propose are the first to determine whether there is a difference between the 2 main types of aortic valve replacement, in terms of prosthetic valve function, durability, and clinical outcomes. If this study demonstrates that TAVR is at least as good as SAVR, this will validate TAVR as a valuable option for the treatment of people with BAV.
Competitiondate
202409
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pibarot, Philippe J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~